Tuesday, 7 July 2015

Asia Pacific, Africa, and Latin America to Drive the Demand from the Global X-Ray Market

Transparency Market Research has published a latest report on the global X-ray market. The report titled “X-ray Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022” forecasts that the global X-ray market will show consistent growth at a CAGR of 4.5% during the period between 2014 and 2022. The market was worth US$7.89 billion in 2013 and with the estimated growth rate, the global X-ray market will reach US$11.79 billion by the end of 2022.

The report credits the growth of the global X-ray market to the rising prevalence of cardiovascular, dental, respiratory, and other diseases across the globe. Also, rising geriatric population will drive the demand from the global X-ray market. Analog X-ray machines which dominated the market till 2005 were replaced by the digital X-ray systems. The high spatial resolution and requirement of minimum X-ray dosage offered by the advanced X-ray systems are preferred by the doctors, thereby fuelling the growth of the global X-ray market. However, the report suggests that the implementation of the legal provisions such as the Affordable Care Act in the U.S., will negatively impact the global X-ray market. The high cost of the advanced digital X-ray systems will lead to its lower adoption rate in the medical sector.

Browse the full X-ray Market Report at

Depending upon the product type, the global X-ray market has been segmented into stationary X-ray and portable X-ray. The portable X-ray segment has been further sub-categorized into mobile X-ray and handheld X-ray. The study compares the market revenue by product type during the period between 2012 and 2022. Due to the cost-effectiveness, the stationary X-ray machines accounted for the largest share of the global X-ray market in 2013. On the basis of technology, the global X-ray market offers analog X-ray and digital X-ray machines. The report identifies the digital X-ray segment to be the fastest growing segment of the global X-ray market during the forecast period. Digital X-ray machines use X-ray sensors to function and store images. Introduction of picture archiving and communication system (PACS) in digital X-ray machines will drive the growth of this segment in the near future.

The report also gives insights about the X-ray detectors market. The global X-ray detectors market has been segmented into photostimulable storage phosphor detectors, flat panel detectors, and others. The flat panel detectors have been further segmented into direct flat panel detectors and indirect flat panel detectors. Other detectors include scintillators, image intensifiers, and, CCD and CMOS-based detectors. The report provides an overview of the global X-ray market by applications and estimates the market revenue in cardiovascular, respiratory, dental, mammography, and other X-ray applications.



Globally, the X-ray market has been divided into Asia Pacific, Europe, North America, Latin America, Africa, and the Rest of the World. Due to the awareness about advanced radiology procedures coupled with high income levels, North America dominated the global X-ray market in 2013. According to the report, emerging economies in Latin America, Africa, and Asia Pacific will lead to huge growth opportunities in the global X-ray market. The report profiles some of the key players of the global X-ray market such as GE Healthcare,Philips Healthcare, Siemens Healthcare, FUJIFILM Holdings Corporation, and Canon Inc.



About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact

Mr. Nachiket Ghumare
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Monday, 6 July 2015

Growing Incidence of Congestive Heart Failure Drives Global Dilated Cardiomyopathy Therapeutics Market

Dilated cardiomyopathy is a condition strongly related to heart attacks, in which the ventricles are enlarged, resulting in a thinning of cardiac walls, and insufficient pumping of blood. Dilated cardiomyopathy can occur at any age, though it is most common in the 20-40 demographic. One of the major reasons of dilated cardiomyopathy is genetic. Some other factors that can cause dilated cardiomyopathy are thyroid disorders, viral infections of the heart, diabetes, alcoholism, and heart valve malformations.

Browse Full Global Dilated Cardiomyopathy Therapeutics Market Report With Complete TOC @ http://www.transparencymarketresearch.com/dilated-cardiomyopathy-market.html


Angiotensin II Receptor Blockers Held Largest Share of Dilated Cardiomyopathy Therapeutics Market in 2013 by Revenue

The dilated cardiomyopathy therapeutics market worldwide is segregated on the basis of drug class, pipeline drugs, and geography. The dilated cardiomyopathy therapeutics market globally in terms of drug class is broadly classified as angiotensin-converting enzyme (ACE) inhibitors, beta blockers, aldosterone antagonists, and angiotensin II receptor blockers (ARBs). Of all the drug class, angiotensin II receptor blockers held the largest share of the dilated cardiomyopathy therapeutics market in 2013 by revenue, followed by beta blockers.

The high demand for the leading drugs for the treatment of dilated cardiomyopathy from developed regions such as Europe and North America is a reason for the large market shares of these classes of drugs. When used in combination either with ACE or ARBs, aldesterone antagonist drugs have proven to have a positive impact on the reduction of progressive conditions such as Duchenne muscular dystrophy (DMD).

The global dilated cardiomyopathy therapeutics market was worth US$651.0 million in 2013. By 2020, the global dilated cardiomyopathy therapeutics market is projected to be worth US$328.6 million which shows a decline of 7% CAGR from 2014 to 2020.

Clinical Trials May Halt Expected Reduction of Dilated Cardiomyopathy Therapeutics Market

The dilated cardiomyopathy therapeutics market worldwide is driven by growing incidence of congestive heart failure which is significantly related with DCM. On a global scenario, dilated cardiomyopathy is associated to 30% to 40% for congestive heart failure cases every year. Due to the growing incidence of congestive heart failure worldwide, several companies have initiated clinical trials for the advancement of therapeutics for dilated cardiomyopathy.

Some of the clinical trials undertaken are a phase II study by Array BioPharma in 2015 for its drug class ARRY-371797, a phase II study by Celladon Corporation in 2014 for its drug class MYDICAR. The dilated cardiomyopathy therapeutics market is expected to get a boost on the successful completion of these clinical trials. However, implantable devices such as heart pumps, pacemakers, and advancement in gene therapy will restrain the growth of dilated cardiomyopathy therapeutics market.

Browse Full Press Release Report :

North America Leads Global Dilated Cardiomyopathy Therapeutics Market

According to geographical segmentation, the dilated cardiomyopathy therapeutics market is divided into four regions, which are Asia Pacific, Europe, North America, and Rest of the World (RoW). North America held the largest share of the dilated cardiomyopathy therapeutics market in 2013 owing to rising cases of heart diseases and acceptance for branded drugs.

The U.S. and Canada make up the dilated cardiomyopathy therapeutics market in North America. The prevalence of DCM in the U.S. is high; 5-8 people out of every 100,000 are diagnosed with DCM. In Canada, heart failure accounts for 9% of total deaths in the country, which is driving the dilated cardiomyopathy therapeutics market in North America.

In Europe, countries such as Spain, Germany, the U.K., and Italy contribute significantly towards the growth of the dilated cardiomyopathy therapeutics market. The dilated cardiomyopathy therapeutics market is growing in Asia Pacific and Rest of the World (RoW) owing to rising economic power, higher incomes, and growing demand for generic drugs.

Some of the key players in the dilated cardiomyopathy therapeutics market are Teva Pharmaceutical Industries Ltd , Merck & Co., Inc., Array BioPharma, Inc., Celladon Corporation, GlaxoSmithKline plc, Pfizer, Inc., Janssen Pharmaceuticals, Inc., Novartis International AG, Sanofi S.A., AstraZeneca plc and Vericel Corporation.


About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

North America Spearheading the Global Kidney Cancer Drugs Market


Kidney cancer is considered to be one of the 10 most common cancers affecting men and women across the globe. While the risk of kidney cancer is higher in men than in women, there are numerous factors that determine the risk of cancer. The two main types of kidney cancer are renal cell carcinoma (RCC) and transitional cell carcinoma (TCC), and kidney cancer drugs are generally administered to patients of stage four, advanced RCC.

Browse Full Global Kidney Cancer Drugs Market Report With Complete TOC @ http://www.transparencymarketresearch.com/kidney-cancer-drugs-market.html


According to the American Cancer Society, in the year 2015, approximately 61,560 new cases of kidney cancer will be registered in the United States alone, of which 23,290 will be women and 38,270 will be men. Out of these, around 14,080 people will die from the disease in 2015, of which 5,010 will be women and 9,070 will be men.

The U.S. National Cancer Institute states that kidney cancer is more common among American Indian, African American, and Alaska Native populations. This makes North America a rather large and lucrative market for kidney cancer drugs.

Votrient: Most promising commercially available kidney cancer drug

There are a number of kidney cancer drugs that are prescribed, used, and commercially available today. Some of the major brands are Votrient (Pazopanib), Inlyta (Axitinib), Proleukin (Aldesleukin), Afinitor (Everolimus), Sutent (Sunitinib), Nexavar (Sorafenib), Torisel (Temsirolimus), and Avastin (Bevacizumab).

Of these, Sutent (Sunitinib) dominated the kidney cancer drugs market in 2013, accounting for 30% of the revenue share. Often considered to be the first line of treatment for renal cell carcinoma (RCC), Sutent is one of the most studied kidney cancer drugs for multiple indications. However, owing to its relatively high price, this drug is expected to register a rather meager growth rate of 1.1% from 2012 to 2016 and 2.1% from 2016 to 2020.

Votrient (Pazopanib), on the other hand, is projected to be the most promising kidney cancer drug during the forecast period and will witness the strongest growth between 2012 and 2020. According to a report by Transparency Market Research (TMR), Votrient is estimated to grow at an outstanding CAGR of 41.7% from 2012 to 2016, and 8.9% from 2016 to 2020.


U.S. largest pharmaceutical market in the world

The global kidney cancer drugs market is divided into four key geographic regions: North America, Europe, Asia-Pacific, and Rest of the World. The growing prevalence of kidney cancer makes North America the leading market for kidney cancer drugs; revenue-wise, this region held more than 45% of the total share in 2013. Split into Canada and the United States, the North America market is driven by a growing patient pool, commercial availability of leading drugs for the treatment of kidney cancer, a strong healthcare insurance base, and impressive healthcare systems customized for the pharmaceutical sector. The U.S. accounted for 90% of the North America kidney cancer drugs market.

The APAC region has also proved to be a lucrative market for kidney cancer drugs owing to a rising geriatric population, growing prevalence of kidney cancer, and economic recovery and growth in countries such as China, Japan, Australia, and New Zealand. Registering a 6% growth rate, the Asia-Pacific market for kidney cancer drugs is anticipated to be the fastest growing regional segment during the forecast period.

Market to register healthy growth rate owing to intense competition

The recently-published TMR report has indicated that the market for kidney cancer drugs is characterized by strong competition among industry participants. With the global market being immensely consolidated, there are only a handful of established pharmaceutical companies who dominate the kidney cancer drugs market. Some of the principal players operating in the market are GlaxoSmithKline, plc, F. Hoffmann-La Roche, Ltd., Pfizer, Inc., Bayer AG, and Novartis AG. Among these, Pfizer was the largest maker of kidney cancer drugs in the world and held more than 40% of the total market share in 2013.

The report states that this concentration of power in the hands of a few contributes to the growth of the kidney cancer drugs market. In 2013, the global market was valued at US$2.6 billion and this is estimated to reach US$4.5 billion by 2020, expanding at a compound annual growth rate of 6.6% till 2020.


About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact

Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Human Papillomavirus and Cytomegalovirus Therapeutics Market on the Rise Owing to Alarming Transmission of DNA Viruses among Global Population


Rising incidence of human papillomavirus (HPV) infections in developing as well as underdeveloped economies and increased seroprevalence have respectively driven the global human papillomavirus and cytomegalovirus therapeutics market over recent years, states a recently published report by Transparency Market Research. The report is titled “Human Papillomavirus and Cytomegalovirus Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020” and is available for sale on the company website.According to the research report, the global HPV therapeutics market was worth US$1.40 billion in 2013 and is projected to be worth US$2.34 billion in 2020, growing at a 7.7% CAGR during the report’s forecast period of 2014 to 2020. The CMV therapeutics market, on the other hand, stands to grow from US$0.87 billion in 2013 to US$0.92 billion in 2020 at a meager CAGR of 1.5% between 2014 and 2020.

The HPV therapeutics market is segmented on the basis of drug class, application, and pipeline drugs. In terms of revenue, immunomodulators were the dominant drug class in 2013 owing to cost-effectiveness, increased efficiency, and its nature as a non-invasive treatment. Application-wise, the segment of genital warts held the largest share of the HPV therapeutics market that year.Application, antiviral drugs, and pipeline drugs are the criteria based on which the CMV therapeutics market is segmented. Among the major antiviral drugs, ganciclovir and valganciclovir held the largest share of the CMV therapeutics market in 2013, while retinitis was the biggest application segment of the CMV therapeutics market that year.

The global HPV and CMV therapeutics market is segmented into five major regions: North America, South America, Europe, Asia Pacific, and Rest of the World. North America led the global HPV and CMV therapeutics market in 2013 in term of revenue. The HPV market in the region is driven by a rise in the sexually active population, increase in diagnostic rate, and growing international migration. The CMV therapeutics market in North America is fueled by increasing cost of drugs, rise in organ transplant surgeries, and high risk of STDs. The South America and Asia Pacific region are both estimated to witness significant growth in the HPV and CMV therapeutics market by 2020.



Clinigen Group plc, Perrigo Company plc, Roche Holdings AG, Merck & Co., Inc., AbbVie, Inc., Actavis plc, and Valeant Pharmaceuticals International, Inc. are the companies profiled in the HPV and CMV therapeutics market report. The CMV therapeutics market was dominated by Roche AG in 2013, thanks to Valcyte being the sole branded formulation available in the market. The HPV therapeutics market was led by Valeant Pharmaceuticals in 2013, owing to the success of its leading brands Aldara, Zyclara, Efudex, and Carac.Each of the players featured in this report are profiled based on attributes such as company and financial overview, product portfolio, recent developments, and business strategies such as mergers and acquisitions, geographic expansions, R&D practices, collaborations and agreements, and product launches.


About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact

Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Sunday, 5 July 2015

Meningococcal Vaccines Market Expected to Reach USD 4.4 Billion Globally in 2022

According to a new report published by Transparency Market Research “Meningococcal Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022,” the meningococcal vaccines market was valued at USD 1.5 billion in 2013 and is expected to reach a value of USD 4.4 billion in 2022, growing at a CAGR of 12.4% from 2014 to 2022.

Browse the full Meningococcal Vaccines Market Report at http://www.transparencymarketresearch.com/meningococcal-vaccines-market.html


Meningococcal disease is caused by the bacterium Neisseria meningitidis and occurs sporadically throughout the world with seasonal variations. It accounts for a proportion of endemic bacterial meningitis, which can progress very rapidly leading to death within 24 hours from the onset of symptoms. The disease is often misinterpreted as common flu in most of the cases. Five out of the several serogroups are known to cause meningococcal disease. The serogroups responsible for causing the disease comprise A, B, C, Y and W-135. The causative agent N. meningitidis is commonly found in the nasopharynx of humans and gets transmitted through droplet inhalation by means of close contact such as exposure to smokers, crowded living conditions such as dormitories, certain inherited disorders of the immune system, functional/anatomical asplenia or through intimate oral contact among others. According to the European Federation of Pharmaceutical Industries and Association, every year, meningitis affects almost 500,000 people globally, primarily affecting toddlers, infants and young adults, due to weaker immune system.

The global market for meningococcal vaccines is segmented broadly into vaccine types namely, polysaccharide, conjugate, combination and Men B vaccines. The report also provides analysis for vaccine under development, NmVac4-DT by JN- International that is expected to be commercialized during the forecast period 2014 to 2022. The vaccine types are further segmented by different brands available in the market. The conjugate vaccines segment is likely to lead the overall meningococcal vaccines market in terms of revenue, which is estimated to be worth USD 2,655.0 million by 2022 at a CAGR of 8.9%. According to Department of Health, U.K., Bexsero is the first serogroup B vaccine to be incorporated into the national immunization program and is expected to be available in the market for sales post settle of price negotiations. The U.S. FDA recently approved two Men B vaccines: Trumenba by Pfizer in October 2014 and Bexsero by Novartis in January 2015.

Browse the full Press release Report :

The market for meningococcal vaccines is largely driven by increasing government intervention in reforming the healthcare infrastructure and incorporation of legislations specific to meningococcal vaccination. The public-private partnerships for conducting research and development, and manufacturing of quality vaccines at an affordable price are also contributing positively in driving market growth. Awareness campaigning from government and non-profit organizations, and obligatory immunization for individuals heading to Mecca (for Hajj pilgrimage) and the South African meningitis belt will also contribute to growth of this market. High cost of few but vital vaccines, such as Bexsero, and need for efficient cold chain logistics to maintain safety and efficacy of the vaccine are expected to be some of the major factors posing a challenge to the adequate uptake of these vaccines.

meningococcal-vaccines-market


The key players dominating the global meningococcal vaccines market include Sanofi Pasteur (the vaccine division of Sanofi SA), Novartis International AG and GSK plc. These players account for more than 90% of the meningococcal vaccines market. Players such as Serum Institute of India Ltd., JN International Medical Corporation, Biomed Pvt. Ltd., Nuron Biotech and Baxter account for the remaining market share.

The global meningococcal vaccines market is segmented as follow:

Meningococcal Vaccines Market, by Type
Polysaccharide Vaccines, by Brand
Menomune
Mencevax
NmVac4
Others
Quadri Meningo
Bi Meningo
Conjugate Vaccines, by Brand
Menactra
Menveo
NeisVac-C
Nimenrix
Meningitec
Menjugate
MenAfriVac
Combination Vaccines, by Brand
MenHibrix
Menitorix
NmVac4-DT
Men B Vaccines, by Brand
Bexsero
Trumenba
Meningococcal Vaccines Market, by Geography
North America
U.S.
Canada
Europe
U.K.
Germany
Rest of Europe
Asia Pacific
Japan
Australia
Rest of Asia Pacific
Rest of the World
Latin America
Africa
Rest of RoW


About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Wednesday, 1 July 2015

Antibacterial Drugs Market Expected to Reach USD 38.9 Billion Globally in 2023

According to a new market report published by Transparency Market Research “Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023,” the global antibacterial drugs market was valued at USD 43.9 billion in 2014 and is estimated to reach USD 38.8 billion by 2023 at a CAGR of (1.3%) from 2015 to 2023.

Antibacterial drugs have been utilized by humans since the discovery of the first antibiotic penicillin in 1928 by Alexander Fleming and has evolved into a multi-billion dollar market. These drugs treat infectious diseases caused by gram positive, gram negative, aerobic and anaerobic bacteria that cannot be treated by any other method unlike other diseases, where substitute methodologies are available. This property has made antibacterial drugs an indispensable part of human health care. Over the period, the bacteria have genetically mutated giving rise to multi-drug resistant (MDR) variants. The prevalence of MDR bacterial infections is also on a hike; according to World Health Organization (WHO) in 2013, there were about 480 000 new cases of multidrug-resistant tuberculosis (MDR-TB); extensively drug-resistant tuberculosis (XDR-TB) has been identified in 100 countries. MDR-TB requires treatment courses that are much longer and less effective than those for non-resistant TB.

Browse the Antibacterial Drugs Market Report at http://www.transparencymarketresearch.com/antibacterial-drugs-market.html

Antibacterial drugs are classified into eight major classes, namely, aminoglycosides, B-Lactams, tetracyclines, sulfonamides, quinolones, macrolides, phenicols and miscellaneous antibacterials. The B-lactams class was the largest segment of the global antibacterial drugs market in 2014, with 58% share. Quinolones was identified as the second largest class, which held a share of 17% of the global antibacterial drugs market in 2014 and is expected to report a negative CAGR during the forecast period. This decline in revenue will be primarily witnessed due to sales erosion from patent expiries, evolution of resistant strains of bacteria and rising concerns regarding tendon ruptures and tendon damage from fluoroquinolones administration. However, the demand for macrolides and quinolones/fluoroquinolones classes will remain high during the forecast period, due to their usage in treating a large number of infections coupled with expected launch of pipeline drugs in these classes during the forecast period.

The key drugs in pipeline have been identified for this market (currently in phase III clinical trials) and sales forecast has been provided for those expected to be launched during the forecast period (2015 to 2022). These include solithromycin (Cempra, Inc.), VivaGel (SPL7013) (Starpharma Holdings Limited), surotomycin (Merck & Co.), MK-3415A (Merck & Co.) and others. These drugs promise to provide improved efficacy, shorter onset of action and fewer side effects as compared to the currently available antibacterial drugs. Hence, future commercialization of these drugs during the forecast period is anticipated to have a profound impact on the growth of the overall antibacterial drugs market.

AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer, Inc., and Sanofi are the major players operating in the global antibacterial drugs market. These players have worldwide presence in the pharmaceutical industry and are involved in constant competition with each other. Pfizer, Inc. was observed to be the leading player in the antibacterial drugs market. Major end-users for antibacterial drugs include hospitals, private clinics, physicians and patients.

Browse the full Antibacterial Drugs Market (By Class- Aminoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones/ Fluoroquinolones, Macrolides, Phenicols and Miscellaneous



The global antibacterial drugs market has been segmented as below:

Global Antibacterial Drugs Market, by Drug Class, 2013 – 2023 (USD Million)
Aminoglycosides
B-Lactams
Tetracyclines
Sulfonamides
Quinolones/Fluoroquinolones
Macrolides
Phenicols
Miscellaneous Antibacterials
Pipeline Analysis of Antibacterial Drugs Market
Actoxumab/Aezlotoxumab, (MK-3415A)
Surotomycin (MK-4261)
Arikace
Cadazolid
Ciprofloxacin/Fluocinolone Acetonide
Zempia (E-101)
Carbavance (meropenem/RPX7009)
Ozenoxacin
RHB-105
SPL7013
Delafloxacin
Solithromycin (CEM-101)
Eravacycline
Delamanid
SYM-1219
Omadacycline (PTK-0796)
Plazomycin
Global Antibacterial Drugs Market, by Geography, 2013 – 2023 (USD Million)
North America
U.S.
Canada
Europe
U.K.
Germany
Rest of Europe
Asia-Pacific
China
Japan
Rest of Asia Pacific
Latin America
Brazil
Rest of Latin America
Rest of the World (RoW)




About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Mr. Nachiket Ghumare
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

Sterilizers and Surgical, Dental Care and Equipment Disinfectors Market to Reach INR 1,390.2 Crore in 2020

According to a new market report published by Transparency Market Research “Sterilizers and Surgical, Dental Care and Equipment Disinfectors Market - India Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020” the sterilizers and surgical, dental care and equipment disinfectors market in India was valued at INR 806.0 Crore in 2013 and is estimated to reach a market worth of INR 1,390.2 Crore in 2020 increasing at a CAGR of 8.2% from 2014 to 2020.

Rising incidence of hospital acquired infectious diseases and increase in the number of surgeries in hospitals is expected to drive the sterilizers and surgical, dental care, and equipment disinfectors market in India. Factors that drive the growth of the sterilization equipment and disinfectants market in India are large pool of geriatric population, rise in prevalence of cancer and increasing number of hospital-acquired infections (HAIs). Furthermore, increase in per capita healthcare expenditure would also propel the growth of this market. According to Trading Economics, disposable personal income in India increased to approximately INR 80,663,730 million in 2012 from INR 71,787,870 million in 2011. Additionally, the market is likely to witness steady growth in technological advancements such as introduction of radiation-based sterilization techniques (gamma and E-beam sterilization) during the forecast period due to high product compatibility and low cost. Negligence towards sterilization measures in hospitals might restrain market growth. Moreover, increasing acceptance of single use and disposable medical device is another major restraint to the chemical sterilizers market.

sterilizers-surgical-dental-care-equipment-disinfectors-market

Government measures to provide adequate healthcare services in remote parts of nation have substantially increased the number of hospitals in the last few years. Furthermore, growing medical tourism in India is also driving the market growth. To further elucidate, heart bypass surgery in India costs USD 5,200 (approx. INR 3.3 Lakhs) while it costs USD 144,000 (Approx. INR 91 Lakhs) in the U.S. Low treatment cost in India is attracting patients across the world and is expected to drive growth of the sterilizers and surgical, dental care, and equipment disinfectors market during the forecast period. According to an article published by the Times of India in September 2014, India is among the top three medical tourism destinations in Asia, primarily due to low cost of treatment, availability of highly skilled specialists, and sophisticated health care infrastructure. However, growing inclination towards single use and disposable instruments due to its consistency and safety has affected the India sterilizers and surgical, dental care and equipment disinfectors market in last few years.

Chlorhexidine gluconate, alcohol, povidone-iodine, benzalkonium chloride, octenidine hydrochloride, ethyl-hexadecyl-dimethyl ammonium and others (aldehydes, hydrogen peroxide, hypochlorites and chlorine based disinfectors) collectively form the chemical formulations market; among which chlorhexidine gluconate based formulations accounted for the largest market share and is expected to lead the position during the forecast period due to the high safety, better efficacy and high usage adoption rate among hospitals and patients. Similarly, within the general hospitals application segment usage of chemical sterilizers and disinfectors were observed to be highest in wound care. Increasing number surgical procedures and rising number of trauma cases are few of the major factors that are boosting the application of sterilizers and disinfectors in wound care segment. Furthermore, within end-users segment operating rooms, ICUs and nursing tables segment accounted for the largest market share and is anticipated to lead the market during the forecast period due to high usage of chemical disinfectors used for disinfecting the equipment used during surgeries. Similarly, within the surgery stages segment post-operative surgery stage account for the largest market share due to the due to increasing risk of infection caused by a number of microbes, their growing drug resistance, and extended hospital stay after the surgery.

Key players profiled in this research report include 3M, Advanced Sterilization Products Services, Inc., Antrix Hygiene Ltd., Ipca Laboratories Ltd., Medi-Vet Animal Health, LLC, PSK Pharma Private Limited, Raman & Weil Pvt. Ltd., Ranbaxy Laboratories Ltd., Reckitt Benckiser Group plc, Sanosil Biotech Pvt. Ltd., Schülke India Pvt. Ltd., UPS Hygienes Pvt. Ltd., Win-Medicare Pvt. Ltd., and Zep Superior Solutions. The end-users (hospitals) profiled in this study are Apollo Hospitals Enterprise Ltd., Fortis Healthcare Limited, and Wockhardt Hospitals.

Browse the full Sterilizers and Surgical, Dental Care and Equipment Disinfectors Market (By Chemical Formulations, By Applications, By End-users & By Surgery Stages) India Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 report at http://www.transparencymarketresearch.com/sterilizers-surgical-dental-care-equipment-disinfectors-market.html


The India sterilizers and surgical, dental care and equipment disinfectors market is segmented into the following categories:
Sterilizers and Surgical, Dental Care and Equipment Disinfectors Market, by Chemical Formulations
Chlorhexidine Gluconate Based Formulations
Alcohol Based Agents
Povidone-Iodine Based Formulations
Benzalkonium Chloride Based Formulations
Octenidine Hydrochloride Based Formulations
Ethyl - hexadecyl - dimethyl Ammonium Based Formulations
Others (Aldehydes, Hydrogen Peroxide, Hypochlorites and Chlorine Based Disinfectors)
Sterilizers and Surgical, Dental Care and Equipment Disinfectors Market, by Applications
Hospitals
General Hospitals
Wound Care
Burn Care
Ulcer Care
Dental Care Centers
Surgical Care
Diagnostic Care
Veterinary Care Centers
Sterilizers and Surgical, Dental Care and Equipment Disinfectors Market, by End-users
Patients and Caregivers
Hospital and Nursing Staff
Operating Rooms, ICUs and Nursing Tables
Equipment and Devices used during Surgery
Others (Veterinary and Diagnostic Care Centers)
Sterilizers and Surgical, Dental Care and Equipment Disinfectors Market, by Surgery Stages
Pre-operative
Intra-operative
Post-operative


About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Mr. Nachiket Ghumare
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453